



APOLLO HOSPITALS ENTERPRISE LIMITED

6th January 2021

CIN : L85110TN1979PLC008035

The Secretary,
Bombay Stock Exchange Ltd (BSE)
Phiroze Jheejheebhoy Towers,
Dalal Street,
Mumbai - 400 001.
Scrip Code - 508869
ISIN INE437A01024

The Secretary,
National Stock Exchange,
Exchange Plaza, 5th Floor
Plot No.C/1, 'G' Block
Bandra - Kurla Complex
Bandra (E)
Mumbai - 400 051.
Scrip Code-
APOLLOHOSP
ISIN INE437A01024

The Manager
The National Stock
Exchange,
Wholesale Debt Market
Exchange Plaza, 5th Floor
Plot No.C/1, 'G' Block
Bandra - Kurla Complex
Bandra (E)
Mumbai - 400 051.

Dear Sir

Subject: Disclosure under Regulation 30 the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the senior management of the Company is conducting virtual meetings with the Investors from today, 6th January 2021 onwards.

The schedule is subject to changes in case of exigencies, if any on the part of Investors/ Company.

The presentation to be made to the Investors is enclosed and the same is also being uploaded on the Company's website www.apollohospitals.com.

Kindly note of the same.

Thanking You,

Yours faithfully,
For APOLLO HOSPITALS ENTERPRISE LIMITED

S.M. KRISHNAN
VICE PRESIDENT - FINANCE
AND COMPANY SECRETARY

CC : The Secretary,
Luxembourg Stock Exchange,
B.P. 165,
L-2011 Luxembourg.

Ref : ISIN US0376081065 - Rule 144a GDR
ISIN US0376082055 - Reg. S GDR

Securities and Exchange Commission
Division of Corporation Finance
Office of International Corporate Finance
450 Fifth Street, N.W.
Washington, D.C 20549-0302
File No. 82-34893

IS/ISO 9001:2000

Regd. Office :
19, Bishop Gardens,
Raja Annamalaipuram,
Chennai - 600 028.

General Office :
"Ali Towers", III Floor,
#55, Greaves Road,
Chennai - 600 006.

Tel : 044 - 28290956 / 3896 / 6681
Telefax : 044 - 2829 0956
Email : investor.relations@apollohospitals.com
Website: www.apollohospitals.com

A decorative graphic consisting of white lines forming a partial frame around the text.

**CORPORATE
PRESENTATION**
January 2021





DISCLAIMER

The information contained in this presentation is provided by Apollo Hospitals Enterprise Limited (the “Company”) to you solely for your reference. This document is being given solely for your information and for your use and may not be retained by you and neither this presentation nor any part thereof may be (i) used or relied upon by any other party or for any other purpose; (ii) copied, photocopied, duplicated or otherwise reproduced in any form or by any means; or (iii) redistributed, passed on or otherwise disseminated, to any other person without the prior written consent of the Company. Although care has been taken to ensure that the information in this presentation is accurate, and that the opinions expressed are fair and reasonable, the information is subject to change without notice, its accuracy is not guaranteed and has not been independently verified. No representation, warranty, guarantee or undertaking (express or implied) is made as to, and no reliance should be placed on, the accuracy, completeness or correctness of any information, including any projections, estimates, targets and opinions, contained herein, and accordingly, none of the Company, its advisors, representatives or any of its directors assumes any responsibility or liability for, the accuracy or completeness of, or any errors or omissions in, any information or opinions contained herein. None of the Company, its advisors, representatives and its directors, officers, employees or affiliates nor any other person accepts any responsibility or liability (whether arising in tort, contract or otherwise) whatsoever for any loss, cost or damage suffered or incurred howsoever arising, directly or indirectly, from any use of this presentation or its contents or otherwise arising in connection therewith, and makes no representation or warranty, express or implied, for the contents of this presentation including its accuracy, fairness, completeness or verification or for any other statement made or purported to be made by any of them, or on behalf of them, and nothing in this presentation or at this presentation shall be relied upon as a promise or representation in this respect, whether as to the past or the future.

The statements contained in this document speak only as at the date as of which they are made, and the Company expressly disclaims any obligation or undertaking to supplement, amend or disseminate any updates or revisions to any statements contained herein to reflect any change in events, conditions or circumstances on which any such statements are based. By preparing this presentation, none of the Company, its management, and their respective advisers undertakes any obligation to provide the recipient with access to any additional information or to update this presentation or any additional information or to correct any inaccuracies in any such information which may become apparent. This document does not constitute or form part of and should not be construed as an offer to sell or issue or the solicitation of an offer to buy or acquire securities of the Company or its subsidiary or affiliates in any jurisdiction or as an inducement to enter into investment activity. No part of this document, nor the fact of its distribution, should form the basis of, or be relied on in connection with, any contract or commitment or investment decision whatsoever. You acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Company. This document is not financial, legal, tax or other product advice. Any person/ party intending to provide finance/ invest in the Company shall do so after seeking their own professional advice and after carrying out their own due diligence procedure to ensure that they are making an informed decision.

This presentation contains statements that constitute forward-looking statements which involve risks and uncertainties. These statements include descriptions regarding the intent, belief or current expectations of the Company or its officers and information currently available with them including with respect to the consolidated results of operations and financial condition, and future events and plans of the Company. These statements can be recognised by the use of words such as “expects”, “plans”, “will”, “estimates”, “intends” or words of similar meaning. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and actual results may differ from those in the forward-looking statements as a result of various factors and assumptions. Neither the Company nor its affiliates or advisors or representatives guarantees that the assumptions underlying such forward-looking statements are free from errors nor do they accept any responsibility for either the future accuracy of the forward-looking statements contained in this presentation or the actual occurrence of the forecasted developments. You are cautioned not to place undue reliance on these forward looking statements, which are based on the current view of the management of the Company on future events. No assurance can be given that future events will occur, or that assumptions are correct. Neither the Company nor its advisors or representatives assume any responsibility to amend, modify or revise any forward-looking statements, on the basis of any subsequent developments, information or events, or otherwise. Certain numbers in these presentations and materials have been subject to routine rounding off and accordingly figures shown as total in tables and diagrams may not be an arithmetic aggregation of the figures that precede them.

This presentation has not been approved and will not or may not be reviewed or approved by any statutory or regulatory authority in India or by any stock exchange in India. This presentation does not purport to be a complete description of the markets conditions or developments referred to in the material. This presentation includes certain industry data and projections that have been obtained from industry publications and surveys. Industry publications and surveys and forecasts generally state that the information contained therein has been obtained from sources believed to be reliable, but there is no assurance that the information is accurate or complete. Neither the Company nor any of its advisors or representatives have independently verified any of the data from third-party sources or ascertained the underlying economic assumptions relied upon therein. All industry data and projections contained in this presentation are based on data obtained from the sources cited and involve significant elements of subjective judgment and analysis, which may or may not be correct. For the reasons mentioned above, you should not rely in any way on any of the projections contained in this presentation for any purpose.

The distribution of these materials in certain jurisdictions may be restricted by law and persons into whose possession these materials comes should inform themselves about and observe any such restrictions.

The company is proposing, subject to receipt of requisite approvals, market conditions and other considerations, a qualified institutions placement of its equity shares in the near future and is in the process of filing a preliminary placement document with the stock exchanges. This presentation and the information contained herein does not constitute or form part of any offer for sale or subscription of or solicitation or invitation of any offer to buy or subscribe for any securities of the Company, nor should it or any part of it form the basis of, or be relied on in connection with, any contract or commitment whatsoever. This presentation is not a prospectus, a statement in lieu of a prospectus, an offering circular, an advertisement or an offer document under the Companies Act, 2013, and the rules made thereunder, as amended, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, or any other applicable law in India. This presentation is not an offer of securities for sale in the United States. Securities may not be offered or sold in the United States absent registration or an exemption from registration.

By accessing this presentation, you accept that this disclaimer and any claims arising out of the use of the information from this presentation shall be governed by the laws of India and only the courts in Chennai, India, and no other courts, shall have jurisdiction over the same.



KEY HIGHLIGHTS

01

Leading private sector
healthcare services
provider

02

Attractive industry
opportunity

03

Excellence in practice

04

Superior operating &
financial track record

05

Strong management
team

06

Strategy for **future
growth**



01

**LEADING PRIVATE SECTOR
HEALTHCARE SERVICES
PROVIDER**



BUSINESS AT A GLANCE

Data as of Mar 31, 2020 except for Apollo 24X7 that is as of Nov 30, 2020

Healthcare Services

53%¹
of revenue



Pharmacy platform

41%¹
Of revenue



Apollo Health and Lifestyle

6%¹
Of revenue



Apollo 24x7



Revenue⁵ FY20: INR 112bn


EBITDA⁵ FY20: INR 13bn

Note: ¹ Including proforma for Apollo Gleneagles Hospital Limited, Kolkata (50% holding), Delhi (22% holding) & Medics International Life Sciences Limited (50% holding) whose Revenues are not consolidated under Ind AS due to joint control; ² 70 hospitals as at end Q1FY21, one 17 bedded hospital in Chennai closed down; ³ Calculated as Total occupied bed days / total operating bed days for owned hospitals; ⁴ ALOS: Average length of stay in hospitals; ARPOB: Average revenue per occupied bed excluding fees paid to fee-for-service consultants; ⁵ Financials prior to reorganization of Standalone Pharmacy business. As part of reorganization company divested its interest in front-end portion of stand-alone pharmacies business to Apollo Pharmacies Ltd, of which they own 25.5% through its associate, Apollo Medicals Private Limited and remaining interest is held by 3 other investors (Detailed structure on Slide 34), EBITDA is pre IND-AS 116




LARGEST PRIVATE HEALTHCARE SERVICES PROVIDER IN INDIA

Leading player in India in terms of number of hospitals



Leading player in India in terms of number of beds available



Source: CRISIL Research


Note: Data as of Fiscal 2020; ¹ 70 hospitals as at end Q1FY21, one 17 bedded hospital in Chennai closed down; Number of hospitals include only owned & managed hospitals in India. The numbers above exclude primary healthcare centers and clinics; ² Data as of Fiscal 2020, Beds from owned and managed hospitals in India only. Max Healthcare Institute includes beds in associate trust owned hospitals




PAN INDIA PRESENCE

Steadily increasing footprint supporting meaningful upside in future


71 hospitals¹ present across India



Healthy mix by category



Healthy mix by vintage (owned hospitals)




Note: Data as of Mar 31, 2020; ¹ 70 hospitals as at end Q1FY21, one 17 bedded hospital in Chennai closed down; ² Internally company classifies any hospital commissioned prior to 8 years as mature hospital



LARGEST PHARMACY PLATFORM IN INDIA


Extensive Pharmacy network also supports the growth of Apollo 24X7 – Digital pharmacy platform

Largest pan-India pharmacy network



Note: Data as of Mar 31, 2020

Highly differentiated business model driving growth



Highly strategic partnership with Pharmacy Platform

- Exclusive supplier to Apollo Pharmacy Ltd (25.5% stake)
- Backend supply chain housed with AHXL
- Agreement to license "Apollo Pharmacy" brand
- Substantial majority of combined revenue & profits to be captured in AHXL



02

ATTRACTIVE INDUSTRY OPPORTUNITY




HUGELY UNDER-PENETRATED MARKET WITH ATTRACTIVE DYNAMICS

Private sector players are well-positioned to leverage opportunity given low contribution of government spending


Growing Indian Healthcare Delivery industry

The healthcare delivery industry has **grown at CAGR of 12-14%** over FY16-20E and is expected to reach **INR 7.3trn by fiscal 2024**




Public healthcare expenditure is low, with private sector accounting for bulk

India Healthcare expenditure




Out-of-pocket expenses as % of Healthcare expenditure




India spends too little on its healthcare

Healthcare expenditure as % of GDP



Per capital healthcare expenditure (in \$)




Source: CRISIL research
 Note: Healthcare expenditure data as of 2018; Per-capita data at an international dollar rate, adjusted for purchasing-power parity




LARGE MARKET WITH STRONG GROWTH PROSPECTS

India lags behind other developed and emerging economies in healthcare infrastructure



Deaths due to disease is higher while healthcare infrastructure is poor

India's share as percentage to world



Source: CRISIL research

Note: India bed density is estimated by CRISIL Research; Bed Density data as of 2017; Annual no. of deaths in India (2017) caused due to disease have been considered as compared to that of the world


RAPID DEMAND GROWTH DRIVEN BY DEMOGRAPHIC SHIFTS, CHANGING CONSUMPTION PATTERNS, INCREASING AFFORDABILITY AND FAVORABLE REGULATORY ENVIRONMENT



Non-communicable disease accounts for most number of deaths


Causes of death in India

- Communicable diseases
- Cardiovascular diseases
- Others
- Cancer
- Other non-communicable diseases




Population in 60+ age group to grow faster

- 0-14 years
- 14-29 years
- 30-44 years
- 45-59 years
- 60+ years



Growing health insurance penetration to propel demand

Population-wise distribution amongst various insurance business (million)



Pradhan Mantri Jan Arogya Yojana adds a demand impetus



~23,289
Hospitals
empanelled



~10mm
Treatments



INR 13,412cr
Claims worth



~125mm
Cards

Strategic partnerships to spread awareness, technology partnership and industry partnerships


Higher health insurance penetration allows greater access to quality healthcare



INDIA OFFERS SIGNIFICANT OPPORTUNITY FOR GROWTH OF MEDICAL TOURISM


India is fast emerging as a major medical tourist destination

Medical tourists (in mn)



~63% of medical tourism demand from neighboring countries

Break-up of medical tourists by major regions of origin



India enjoys a cost advantage globally with control over quality

| Ailments (US\$) | US | Korea | Singapore | Thailand | India |
|-------------------------|---------|--------|-----------|----------|-------|
| Hip replacement | 50,000 | 14,120 | 12,000 | 7,879 | 7,000 |
| Knee Replacement | 50,000 | 19,800 | 13,000 | 12,297 | 6,200 |
| Heart bypass | 144,000 | 28,900 | 18,500 | 15,121 | 5,200 |
| Angioplasty | 57,000 | 15,200 | 13,000 | 3,788 | 3,300 |
| Heart valve replacement | 170,000 | 43,500 | 12,500 | 21,212 | 5,500 |
| Dental implant | 2,800 | 4,200 | 1,500 | 3,636 | 1,000 |

Source: CRISIL research

Note: ¹ Includes medical visa and medical attendant visa

01

Medical tourism market in India to **rise at a CAGR of 65-70%** between **fiscals 2021 and 2025**

02

Treatments mostly sought after in India are **high end treatments pertaining to complex ailments** like heart surgery, knee implant, cosmetic surgery and dental care, due to the **low costs of treatments** in India

03

Growth in medical tourism expected primarily due to (i) **Technologically advanced** hospitals (ii) highly **skilled doctors**; (iii) **lower cost** of treatment and (iv) **e-medical visas** (v) **holistic wellness** - traditional healthcare therapies (Ayurveda & Yoga) combined with allopathic treatments

04

Medical tourist from **South and West Asia** region continue to constitute **majority share**




OPPORTUNITY FROM INCREASING DIGITAL ADOPTION AIDED BY FAVORABLE CONSUMER BEHAVIOR AND STRONG IMPETUS PROVIDED BY COVID

Data driven revolution in the country has led to a generation of digitally inclined consumer...

Robust internet subscribers growth...

■ Internet users (in mm)



...and rapid tech adoption



556
FY20E



911
FY25P

4G & 5G subscriber base in India
(mm)



~60%

Smartphone
penetration by
2022

... which has been further driven by Covid



Healthcare delivery witnessing an influx of mobile-based applications



Growth in demand for telemedicine and e-pharmacy



Movement towards low touch healthcare model

No. of people using online health consultations



~3 times

between March to
November 2020

No. of users using e-pharmacy website/apps



2.5-3 times

between March and
June 2020



03

EXCELLENCE IN PRACTICE



QUALITY HEALTHCARE SERVICES DELIVERY ON THE BACK OF WORLD-CLASS CLINICAL EXCELLENCE

Leaders in clinical quality & excellence – 8 hospitals received JCI accreditations & 30 hospitals NABH accreditations



- 35 Units
- 10,000+ heart surgeries in FY20



- 36 Units
- 35,000+ Neuro surgical discharges in FY20



- 22 Units with Medical & Surgical Oncology
- 12 Units with Medical, Surgical and Radiation Oncology



- 24 Units
- ~1,400 Solid Organ transplant in FY20




- 39 Units
- 6,500+ Joint replacements in FY20



- 38 Units
- 200,000+ footfalls annually

Significant contribution (60%) from high-end tertiary care practice¹



Key differentiating factors for Centers of Excellence



Note: Data as of Mar 31, 2020; ¹ In-Patient revenue contribution + Out-Patient revenue of Radiation & Chemotherapy




PIONEERS IN TECHNOLOGY ADOPTION

One of the first to adopt robotics precision in minimally invasive surgery



Since its inception, Apollo Hospitals has actively invested and strived to embrace advanced medical technology

SERVICE EXCELLENCE – THE MINTMARK OF APOLLO






04

**SUPERIOR OPERATING &
FINANCIAL TRACK RECORD**




KEY OPERATING METRICS

In-patient admission ('000)




Bed Occupancy Rate %




Average Revenue Per Occupied Bed (ARPOB) (INR per / Day)

Consistent growth in ARPOB



Pharmacies (no. of stores)

Proven ability to expand the store network




Sep 2020 metrics are impacted due to COVID-19

Note: September financials is half yearly data; Average revenue per occupied bed excluding fees paid to fee-for-service consultants;




HEALTHCARE FINANCIAL METRICS

Healthcare Revenue (INR mm) (consolidated)




Healthcare EBITDA (INR mm) (consolidated)




PHARMACY FINANCIAL METRICS

Pharmacy Platform Revenue (INR mm)



Pharmacy Platform EBITDA (INR mm)




Sep 2020 metrics are impacted due to COVID-19

Note: September financials is half yearly data; EBITDA is Pre-IND AS 116; Pharmacy platform includes full pharmacy revenues upto March 2020. Effective 1st Sep 2020, as part of reorganization company divested its interest in front-end portion of stand-alone pharmacies business to Apollo Pharmacies Ltd, of which they own 25.5% through its associate, Apollo Medicals Private Limited, from which time pharmacy platform represents back end pharmacy business



APOLLO HEALTH AND LIFESTYLE – RETAIL HEALTHCARE


Revenue FY20 of INR 6,964mm – Primary Care (33%), Diagnostics (11%) & Specialty Care (57%)






AHEL CONSOLIDATED FINANCIALS – CONTINUOUS GROWTH WITH ROBUST MARGINS


Consolidated Revenue (INR mm)



Consolidated EBITDA (INR mm)



Consolidated Net Income (INR mm)



Sep 2020 metrics are impacted due to COVID-19



05

STRONG MANAGEMENT TEAM



APOLLO HAS ALWAYS BEEN AT THE FORE-FRONT OF DEVELOPMENT OF INDIA'S HEALTHCARE SECTOR

Apollo Impact

- Improved overall availability of private health care services in India
- Better access to care in semi-urban and rural areas



- Equitable access to health services through price differentiation, telemedicine, and CSR initiatives



- First in India to obtain international JCI accreditation




- Attractive destination for medical talent in India and from overseas
- Helped India become the destination of choice for medical tourists





EXECUTIVE BOARD



Dr. Prathap C. Reddy
Executive Chairman, Founder

- Conferred the Padma Vibhushan in 2010
- Conferred the Padma Bhushan in 1991
- Spent 36 years with Apollo Hospitals




Suneeta Reddy
Managing Director

- On the Board since the year 2000



Dr. Preetha Reddy
Executive Vice Chairperson

- On the Board since the year 1989
- 30+ years healthcare experience



Sangita Reddy
Joint Managing Director

- On the Board since 2000



Shobana Kamineni
Executive Vice Chairperson

- On the Board since 2010



INDEPENDENT DIRECTORS



Vinayak Chatterjee
Independent Director

- On the Board since 2014



Bhaskara Mandavilli Nageswara Rao
Independent Director

- On the Board since Feb 2019



Dr. Rajgopal Thirumalai
Independent Director

- On the Board since May 2017



Velagapudi Kavitha Dutt
Independent Director

- On the Board since Feb 2019



Dr. Pudugramam Murali Doraiswamy
Independent Director

- On the Board since Sep 2018



06


STRATEGY FOR **FUTURE
GROWTH**



STRATEGY FOR FUTURE GROWTH (1/2)


Strategy

Mature Hospitals



- **Optimise Asset Utilisation** in facilities & locations
- **Focus on Centers of Excellence** with one or two **anchor specialties** in each market
- **Extend and expand oncology presence** both through specialization and exclusive oncology referral hospitals in the cluster
- **Cost Efficiencies & Focus on Improving Key Operating Metrics**

New Hospitals



- **Strengthen presence and increase market share** in **key strategic markets**
- Recruit relevant **local medical talent** to **augment clinical offerings**



STRATEGY FOR FUTURE GROWTH (2/2)

Apollo Health & Lifestyle (AHL)



929

Primary care centers



27

Specialty care centers

Strategy

- Focus on urban markets; expand in clusters
- Owned clinic models in metros, franchisee clinics in Tier II towns

Pharmacies platform



3,766
Outlets



Strong
distribution



Asset light
model




Robust
supply chain

- Derive economies of scale that arise from the largest pharmacy chain
- Exclusive supplier to APL and license “Apollo Pharmacy” brand
- Enhance Private label business and focus on high prescription fulfilment rates
- Data-driven store expansion and Foray into Digital commerce




APOLLO 24X7 – INDIA’S LARGEST OMNI-CHANNEL HEALTHCARE PLATFORM LEVERAGING PHYSICAL NETWORK

Distinctive digital ecosystem...



- Unique ecosystem extremely difficult to replicate
- Integrated healthcare platform with few parallels globally
- Best positioned to become the largest digital health platform

... coupled with adequate network and capabilities




Integration of digital and physical capabilities provides

- Cost efficiencies through sharing of managerial and clinical resources
- Economies of scale & competitive prices through centralized purchasing
- Access to qualified & trained medical resources and larger patient base



FUTURE GROWTH STRATEGY – TRANSFORMING THROUGH TECHNOLOGY AND CLINICAL EXCELLENCE


Integrated digital strategy leveraging existing network, capabilities and market leadership




-  Focus on investments in advanced technology and innovation – “(re) Invent the health system of the future”
-  Asset Light & Bolt on acquisition led expansion strategy in Tier I, Metros and select Tier II cities in India
-  Focus on high value clinical specialties
-  Improve operating efficiencies and profitability
-  Building deep relationships with the Apollo consumer across category – hospitals, pharmacy, clinics, diagnostics
-  Unlocking potential for up-sell, cross-sell, and loyalty driven behavior using advanced analytics
-  Focus on Clinical Innovations and outcomes



UPDATE ON IMPACT OF COVID-19



 **'Project Stay I'** saw success with over 77,000 room nights

 **Home care** segment enabled people to move into 28,500 homes, (of which COVID care was at 14,600 homes) and provide medically supervised home isolation services

 **Digital healthcare app Apollo 24/7** – agile and digitally connected to the consumer, 2.3 lakh digital consults till date




07

APPENDIX



REORGANIZATION MECHANICS OF PHARMACY PLATFORM BUSINESS

Focus on leveraging full potential of Standalone Pharmacy business as an independent business



Slump sale of front-end business through NCLT process for consideration of ~\$72mm

THANK YOU